import type { ServiceLandingExpandedContent } from '@/data/serviceLandingContent';

export const DEVELOPED_MARKET_MEDTECH_SLUGS = [
  'canada',
  'usa',
  'uk',
  'australia',
  'germany',
  'france',
  'japan',
  'china',
  'singapore',
  'italy',
  'spain',
  'switzerland',
  'denmark',
  'new-zealand',
  'south-korea',
  'poland',
  'malaysia',
  'brazil',
] as const;

export type DevelopedMarketMedtechSlug = (typeof DEVELOPED_MARKET_MEDTECH_SLUGS)[number];

export type DevelopedMarketMedtechCountry = {
  slug: DevelopedMarketMedtechSlug;
  label: string;
  regulatorShort: string;
  marketSize: string;
  domesticFirms: string;
  healthcareResearchPath: string;
  medDevicesReportPath: string;
  relatedSlugs: [DevelopedMarketMedtechSlug, DevelopedMarketMedtechSlug];
  languages: string;
  metricOne: { label: string; value: string; detail: string };
  metricTwo: { label: string; value: string; detail: string };
  metricThree: { label: string; value: string; detail: string };
  regulatoryParagraphs: string[];
  marketParagraphs: string[];
  executivePoints: Array<{ title: string; body: string }>;
};

const SHARED_DELIVERABLES = [
  'Executive summary mapped to one commercial, access, or portfolio decision',
  'Stakeholder segmentation with influence and objection themes by account type',
  'Quantitative adoption or sizing modules where the objective requires measurement',
  'Qualitative depth interviews with clinicians, biomedical engineers, and procurement',
  'Competitive landscape and switching barrier analysis with segment-level readouts',
  'Audit-ready methodology appendix for internal review or regulator dialogue',
];

function buildServices(label: string, regulatorShort: string) {
  return {
    heading: `MedTech market research services in ${label}`,
    items: [
      {
        title: 'Hospital procurement and formulary committee research',
        description: `Primary research with hospital pharmacy, biomedical engineering, and value-analysis committees — mapping evidence requirements, tender criteria, and total-cost-of-ownership thresholds that govern ${label} device listing decisions.`,
      },
      {
        title: 'Clinician adoption and workflow studies',
        description: `Surveys and depth interviews with procedure specialists, nursing leads, and cath-lab or OR coordinators to quantify adoption drivers, training burden, maintenance contracts, and switching friction for novel technologies.`,
      },
      {
        title: 'Regulatory pathway and competitive intelligence',
        description: `Landscape mapping of ${regulatorShort} classification, predicate devices, notified-body timelines, and competitor MDL/CE/FDA clearance status — translated into launch sequencing and evidence-gap analysis.`,
      },
      {
        title: 'Pricing, reimbursement, and payer-adjacent research',
        description: `Research on provincial, national, or insurer funding pathways for device categories — including technology assessment expectations, DRG/procedure funding, and private-pay carve-outs relevant to your SKU.`,
      },
      {
        title: 'KOL mapping and advisory board programmes',
        description: `Identification and engagement of clinical champions at academic health science centres and high-volume community hospitals, with advisory modules designed for protocol feedback, message testing, and early adopter profiling.`,
      },
      {
        title: 'GCC and MENA expansion intelligence for ${label} manufacturers',
        description: `Comparative research linking ${label} regulatory credentials (including Access Consortium or reference-agency reliance) to SFDA, MOHAP, and GCC hospital procurement pathways — supporting international portfolio committees.`,
      },
    ],
  };
}

function buildMethodology(label: string) {
  return {
    heading: `Methodology for ${label} MedTech market research`,
    paragraphs: [
      `BioNixus anchors every ${label} MedTech programme on a single commercial or access decision — launch sizing, competitive defence, distributor selection, or hospital prioritisation — before fieldwork scales. Feasibility sprints validate respondent availability across target specialties, account types, and geographies within ${label}, documenting sample frames and recruitment risk before protocol finalisation.`,
      `Mixed-method designs combine quantitative surveys for adoption metrics and competitive share-of-voice with qualitative depth for procurement rationale and workflow barriers. Sample sizes target eighty percent power to detect ten-point shifts in adoption intent or committee recommendation likelihood where quant modules apply; qual modules typically run twelve to twenty interviews per stakeholder cell until thematic saturation.`,
      `All physician and hospital stakeholder research in ${label} follows TCPS 2 or equivalent ethics requirements with documented informed consent, de-identified reporting, and secure data handling. Respondent verification includes licence, specialty, and practice-setting confirmation — reducing misclassification risk that undermines syndicated panel data in specialist device categories.`,
      `Deliverables include executive synthesis, segment prioritisation, competitive objection libraries, and a thirty/sixty/ninety-day action plan with evidence gaps flagged. Optional global benchmarking cells run in parallel using harmonised instruments so ${label} insights roll up cleanly for multinational portfolio reviews without losing local execution realism.`,
    ],
  };
}

function buildProcess(label: string) {
  return {
    heading: `Typical ${label} MedTech research programme timeline`,
    steps: [
      {
        title: 'Weeks 1–2: Decision framing and feasibility',
        body: `Commercial objective workshop, stakeholder map, competitive set definition, and written feasibility for target specialties and hospital account types across ${label}.`,
      },
      {
        title: 'Weeks 3–4: Instrument design and ethics',
        body: `Survey and discussion guides calibrated to ${label} procurement and clinical context; ethics submission where required; cognitive pilots before field launch.`,
      },
      {
        title: 'Weeks 5–8: Fieldwork and quality governance',
        body: `HCP, procurement, and optional patient modules with daily recruitment funnel review, respondent verification, and mid-field adjustments if sample frames underperform.`,
      },
      {
        title: 'Weeks 9–10: Analysis and activation',
        body: `Segment readouts, competitive benchmarks, executive workshop, and action plan with owners — plus optional GCC expansion module scoping if international growth is in scope.`,
      },
    ],
  };
}

function buildFaqs(country: DevelopedMarketMedtechCountry): ServiceLandingExpandedContent['faqs'] {
  return [
    {
      question: `Who is the best MedTech market research company in ${country.label}?`,
      answer: `BioNixus is a specialist MedTech and medical devices market research company in ${country.label}, delivering ${country.regulatorShort}-aware hospital procurement research, clinician adoption studies, KOL mapping, and competitive intelligence for manufacturers launching or defending device portfolios. BioNixus combines primary research depth with verified specialist networks across ${country.label} academic health science centres and high-volume community hospitals — with governance suitable for multinational medical affairs and commercial teams.`,
    },
    {
      question: `How does ${country.regulatorShort} regulation affect MedTech market research in ${country.label}?`,
      answer: `Research programmes must reflect how ${country.regulatorShort} classifies and licenses devices — because classification determines review timelines, clinical evidence requirements, and the claims manufacturers can make to hospital committees. BioNixus maps regulatory pathways alongside procurement research so commercial teams understand not only prescriber preference but the evidence committees expect at listing. This integrated view reduces expensive rework when regulatory and access strategies diverge.`,
    },
    {
      question: `What is the typical timeline for MedTech market research in ${country.label}?`,
      answer: `Focused HCP and procurement surveys typically complete in four to six weeks. Full mixed-method programmes including KOL depth interviews, hospital committee modules, and competitive landscaping usually run eight to twelve weeks depending on specialty scarcity, ethics review requirements, and geographic spread across ${country.label}. Complex surgical device categories with multi-site AMC recruitment may require extended planning timelines — feasibility is documented before commitment.`,
    },
    {
      question: `Can BioNixus connect ${country.label} MedTech research to GCC and MENA expansion?`,
      answer: `Yes. ${country.label} manufacturers often leverage Access Consortium or reference-agency credentials when entering GCC markets. BioNixus runs parallel modules comparing ${country.label} adoption dynamics with SFDA, MOHAP, and hospital procurement intelligence in Saudi Arabia and the UAE — using harmonised instruments for global portfolio committees managing multi-market device strategy from one research partner.`,
    },
    {
      question: `Which medical device segments does BioNixus cover in ${country.label}?`,
      answer: `BioNixus covers cardiovascular devices, orthopaedics and joint replacement, diagnostic imaging, in vitro diagnostics, diabetes technology (CGM and insulin pumps), surgical robotics, wound care, digital health and remote monitoring, and hospital capital equipment across ${country.label}. Segment-specific sampling prioritises procedure volume and account types that drive pull-through for each SKU rather than generic hospital averages.`,
    },
    {
      question: `How does BioNixus ensure data quality in ${country.label} physician research?`,
      answer: `BioNixus verifies physician credentials, specialty, and practice setting before inclusion; uses structured screeners aligned to procedure volume where relevant; and applies daily quality-funnel governance during fieldwork. For hospital procurement stakeholders, verification includes role confirmation and institution type. This three-layer approach consistently outperforms unverified panels on specialty alignment and ${country.label}-specific clinical experience.`,
    },
  ];
}

function buildExpandedContent(country: DevelopedMarketMedtechCountry): ServiceLandingExpandedContent {
  return {
    hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
    regulatory: {
      heading: `${country.regulatorShort} and market access context for MedTech in ${country.label}`,
      paragraphs: country.regulatoryParagraphs,
    },
    marketContext: {
      heading: `Why MedTech teams invest in ${country.label} market research now`,
      paragraphs: country.marketParagraphs,
    },
    services: buildServices(country.label, country.regulatorShort),
    methodology: buildMethodology(country.label),
    useCases: {
      heading: `When manufacturers commission MedTech research in ${country.label}`,
      paragraph: `Teams typically engage when a launch, line extension, competitive entry, or international expansion decision requires local evidence beyond syndicated audit data.`,
      areas: [
        'Pre-launch hospital prioritisation and account segmentation',
        'Competitive defence when lower-cost or next-generation entrants threaten share',
        'Distributor and channel partner evaluation',
        'Health technology assessment evidence planning',
        'Procedure growth sizing and capacity mapping',
        'KOL and clinical champion identification for medical affairs',
        'Pricing and total-cost-of-ownership message testing',
        'Global portfolio benchmarking with GCC or EU5 comparators',
      ],
    },
    process: buildProcess(country.label),
    deliverables: {
      heading: 'MedTech research programme outputs',
      bullets: SHARED_DELIVERABLES,
    },
    decisionBlueprint: {
      why: `${country.label}'s ${country.marketSize} MedTech market combines rigorous ${country.regulatorShort} oversight with hospital-level procurement complexity — desk research alone rarely predicts listing outcomes.`,
      evidence: `BioNixus primary research across ${country.label} device categories consistently shows procurement committee objections and workflow friction explain adoption gaps that prescriber surveys alone miss.`,
      next: `Define your target segment, account type, and commercial decision; BioNixus delivers a written feasibility and methodology proposal within one week.`,
    },
    faqs: buildFaqs(country),
  };
}

export const DEVELOPED_MARKET_MEDTECH_COUNTRIES: Record<
  DevelopedMarketMedtechSlug,
  DevelopedMarketMedtechCountry
> = {
  canada: {
    slug: 'canada',
    label: 'Canada',
    regulatorShort: 'Health Canada',
    marketSize: 'USD 13–16 billion',
    domesticFirms: '1,500+ medical device companies (predominantly SMEs)',
    healthcareResearchPath: '/healthcare-market-research-canada',
    medDevicesReportPath: '/canada-medical-devices-market-report',
    relatedSlugs: ['usa', 'uk'],
    languages: 'English and French',
    metricOne: {
      label: 'MedTech market 2026',
      value: 'USD 13–16B',
      detail: 'Top-10 globally; MEDEC / ISED industry profile estimates.',
    },
    metricTwo: {
      label: 'Domestic device firms',
      value: '1,500+',
      detail: 'Highly diversified SME base; strong academic hospital innovation adoption.',
    },
    metricThree: {
      label: 'MDL review (Class IV)',
      value: '300 days',
      detail: 'Health Canada pre-market review for highest-risk devices.',
    },
    executivePoints: [
      {
        title: 'Health Canada MDL gates the revenue case',
        body: 'MedTech launches in Canada hinge on Medical Device Licence classification (Class I–IV), Canadian Importer designation, and MDEL requirements for distributors. Research should map classification, predicate pathways, and MDSAP audit expectations before scaling hospital fieldwork.',
      },
      {
        title: 'Provincial procurement resets net price',
        body: 'Hospital devices are funded within provincial operating budgets and technology assessment processes — not a national formulary. CADTH Health Technology Review and INESSS (Quebec) evaluations inform coverage; Ontario, BC, Alberta, and Quebec each implement distinct procurement rhythms.',
      },
      {
        title: 'Academic health science centres drive early adoption',
        body: 'UHN (Toronto), McGill University Health Centre, Vancouver General, Sunnybrook, and CHUM are among the world\'s leading research hospitals and key early adopters. KOL mapping at these centres predicts national diffusion patterns for novel surgical and diagnostic technologies.',
      },
    ],
    regulatoryParagraphs: [
      'Health Canada\'s Medical Devices Bureau regulates devices under the Medical Devices Regulations (SOR/98-282). Class I devices require establishment registration; Class II devices need a Medical Device Licence (MDL) with approximately fifteen-day review; Class III devices face seventy-five-day pre-market review; Class IV devices — implantables, life-sustaining technologies, and many IVDs — require up to three-hundred-day review with clinical evidence typically expected. Foreign manufacturers must designate a Canadian Importer or Manufacturer responsible for regulatory compliance, and importers and distributors require Medical Device Establishment Licences (MDELs).',
      'Canada participates in the Access Consortium alongside TGA (Australia), MHRA (United Kingdom), HSA (Singapore), and Swissmedic (Switzerland) — enabling international recognition of regulatory submissions and parallel market entry. For manufacturers already cleared in consortium member states, Health Canada reliance pathways can compress review timelines. MedTech market research should align launch sequencing with consortium credentials when global portfolio teams plan multi-market rollouts.',
      'CADTH (Canadian Agency for Drugs and Technologies in Health) evaluates non-drug health technologies — including medical devices — through its Health Technology Review (HTR) process, issuing guidance that provincial health authorities use to inform coverage and procurement decisions. INESSS (Institut national d\'excellence en santé et en services sociaux) conducts equivalent assessments for Quebec, which operates distinct procurement and reimbursement logic from other provinces. Device manufacturers must anticipate both federal HTA expectations and provincial implementation variation.',
      'Medical device reimbursement in Canada operates through provincial healthcare budgets rather than a national device formulary. Hospital devices are typically funded within global hospital operating budgets or provincial technology assessment processes. Provinces operate funded programmes for specific device categories — insulin pumps, CGM systems, hearing aids, prosthetics, and orthotics are variously covered under provincial programs with distinct eligibility criteria. Research that treats "Canada" as a single payer environment systematically misprices access strategy.',
      'Health Canada has aligned clinical investigation requirements for medical devices with ISO 14155 GCP standards, and Canada maintains an active medical device clinical trial ecosystem. PIPEDA and provincial privacy legislation govern patient and real-world data use. BioNixus designs Canadian patient and hospital stakeholder research with documented consent, de-identified reporting, and secure data handling consistent with TCPS 2 research ethics requirements for HCP studies.',
      'The Patented Medicine Prices Review Board (PMPRB) primarily governs patented medicines rather than devices, but provincial budget pressure and CADTH economic expectations increasingly require budget-impact and cost-effectiveness evidence for high-cost implantables and capital equipment. Hospital value-analysis committees apply total-cost-of-ownership frameworks — acquisition price, training, maintenance, disposables, and length-of-stay impact — that differ materially from US GPO tender logic.',
    ],
    marketParagraphs: [
      'Canada\'s medical devices market is estimated at USD 13–16 billion in 2026, ranking among the top ten globally by value. ISED (Innovation, Science and Economic Development Canada) estimates the domestic market (excluding IVD) at approximately USD 10 billion in 2024, accounting for about 2.5% of the global market, with over 1,500 medical device companies operating nationally — predominantly small and medium-sized enterprises engaged in research, development, manufacturing, and distribution.',
      'The market is shaped by provincial healthcare budgets funding device procurement for public hospitals and clinics, alongside private insurance-covered devices for outpatient use. Canada imports approximately seventy percent of domestic demand; the United States supplied roughly forty-two percent of imports in 2024 (CAD 5.9 billion), followed by China, Mexico, and Germany. Cardiology, diagnostic imaging, orthopaedics, dental, ophthalmic, and diabetes care represent the largest import categories — each requiring segment-specific research rather than blended hospital averages.',
      'Canada ranks among the top biomedical research nations — with academic health science centres driving early adoption of novel technologies. Continuous glucose monitoring and insulin pump technology have been major growth segments following expanded provincial coverage programs. Digital health, remote patient monitoring, and connected devices accelerated post-COVID, creating new research needs around clinician workflow integration and provincial funding eligibility.',
      'Ontario (University Health Network, Sunnybrook), Quebec (CHUM, McGill University Health Centre), British Columbia (Vancouver General, BC Cancer), and Alberta (Foothills Medical Centre) concentrate high-volume procedural care and clinical trial activity. MedTech research sample frames should reflect this geographic concentration — national averages obscure the account-level dynamics that determine first-wave adoption for surgical robotics, structural heart, and advanced imaging platforms.',
      'Medtech Canada (formerly MEDEC) represents the national industry association; manufacturers navigating Canadian market entry benefit from research that translates association policy positions and provincial budget cycles into actionable account prioritisation. BioNixus programmes connect prescriber intent data with procurement committee behaviour — closing the gap between clinical enthusiasm and listing outcomes that syndicated audits cannot explain.',
      'Canadian manufacturers expanding internationally — particularly into GCC and MENA markets — leverage Access Consortium alignment with TGA and MHRA decisions that GCC regulators frequently reference. BioNixus supports comparative Canada-versus-GCC commercial strategy, mapping Health Canada MDL credentials to SFDA and MOHAP pathways while researching hospital procurement at key Gulf accounts.',
      'Against global syndicated vendors, BioNixus differentiates on verified specialist recruitment, hospital procurement depth, bilingual English–French fieldwork, and decision-linked synthesis — scoped to the commercial question in front of you rather than a subscription dashboard averaging away provincial nuance.',
      'Launch windows for novel devices often compress when competitor technologies receive CADTH favourable guidance or provincial fast-track procurement during capacity expansion programmes. Longitudinal tracking of committee sentiment and competitor share-of-voice provides leading indicators before tender outcomes and procedure volumes shift in IQVIA or CIHI-derived secondary data.',
    ],
  },
  usa: {
    slug: 'usa',
    label: 'United States',
    regulatorShort: 'FDA CDRH',
    marketSize: 'USD 175–200 billion',
    domesticFirms: 'AdvaMed member companies and thousands of SME device manufacturers',
    healthcareResearchPath: '/healthcare-market-research-usa',
    medDevicesReportPath: '/usa-medical-devices-market-report',
    relatedSlugs: ['canada', 'uk'],
    languages: 'English (Spanish where relevant in border states)',
    metricOne: { label: 'MedTech market 2026', value: 'USD 175–200B', detail: 'Largest globally; AdvaMed / FDA CDRH market estimates.' },
    metricTwo: { label: 'FDA device pathways', value: '510(k) / PMA / De Novo', detail: 'Risk-based classification drives evidence and timeline.' },
    metricThree: { label: 'Hospital GPO coverage', value: '~80%', detail: 'Vizient, Premier, HealthTrust govern hospital purchasing.' },
    executivePoints: [
      { title: 'FDA CDRH pathway defines evidence burden', body: '510(k) predicate strategy, De Novo novelty claims, and PMA clinical trial requirements shape what hospital committees expect at launch. Research must align regulatory class with committee evidence thresholds.' },
      { title: 'GPO and IDN contracting reset utilization', body: 'Vizient, Premier, and HealthTrust contracts govern roughly eighty percent of US hospital purchasing. Account segmentation by GPO affiliation and IDN ownership predicts pull-through better than national prescriber averages.' },
      { title: 'CMS coverage determines Medicare volume', body: 'National Coverage Determinations, Transitional Coverage for Emerging Technology (TCET), and Medicare Administrative Contractor local policies create step-changes in procedure reimbursement that adoption research must anticipate.' },
    ],
    regulatoryParagraphs: [
      'The FDA Center for Devices and Radiological Health (CDRH) regulates medical devices under a risk-based classification system. Class I devices are general controls; Class II typically requires 510(k) premarket notification demonstrating substantial equivalence to a predicate device; Class III requires Premarket Approval (PMA) with clinical trial evidence. The De Novo pathway applies to novel low-to-moderate risk devices without predicates. Breakthrough Device Designation and SaMD (Software as a Medical Device) frameworks add complexity for digital health portfolios.',
      'Quality system regulation (21 CFR 820, transitioning to ISO 13485 harmonisation) and MDSAP audit participation affect manufacturer credibility with US hospital value-analysis committees. Foreign manufacturers exporting to the US require US Agent designation and FDA establishment registration. MedTech market research should map competitive clearance status and predicate chains before message testing — physicians reference FDA labels and indications when evaluating novel technologies.',
      'CMS coverage policy shapes Medicare and Medicaid volume — approximately sixty-five million Medicare beneficiaries plus ninety million Medicaid lives. National Coverage Determinations, local coverage determinations from Medicare Administrative Contractors, and the Transitional Coverage for Emerging Technology (TCET) pathway for devices create distinct access timelines from FDA approval. Commercial payer prior authorisation and step therapy add further friction for outpatient device categories.',
      'Hospital Group Purchasing Organisations (Vizient, Premier, HealthTrust) negotiate national contracts controlling the majority of acute-care purchasing. Integrated Delivery Networks (IDNs) layer system-level formulary decisions atop GPO contracts. Research sample frames must segment by GPO/IDN affiliation, community versus academic setting, and ambulatory surgery centre ownership — national averages obscure the account dynamics that determine listing.',
      'The FDA Unique Device Identification (UDI) system and post-market surveillance requirements (522 studies, MDR reporting) influence hospital compliance expectations and recall response behaviour. Real-world evidence programmes increasingly support payer negotiations and label expansions — particularly for orthopaedic, cardiovascular, and diabetes technology segments where procedure registries exist.',
      'State-level regulations, certificate-of-need laws for capital equipment, and Stark Law / Anti-Kickback Statute constraints on manufacturer-physician relationships affect commercial strategy. BioNixus US research programmes document institutional policies on physician consulting, proctoring, and training that vary materially across IDNs.',
    ],
    marketParagraphs: [
      'The United States medical devices market is estimated at USD 175–200 billion in 2026 — the largest globally — with total health expenditure exceeding USD 5 trillion (17.8% of GDP). Approximately 6,120 hospitals operate nationally with heavy concentration of procedural volume at academic medical centres (Mayo Clinic, Cleveland Clinic, Johns Hopkins, MSKCC) and large IDNs.',
      'Cardiology, orthopaedics, diagnostic imaging, diabetes technology, and surgical robotics represent the highest-value segments. GLP-1 market dynamics indirectly affect diabetes device strategy as pharmacotherapy shifts complicate CGM and pump portfolio planning. Structural heart, electrophysiology, and robotic-assisted surgery drive cath-lab and OR capital investment cycles that research must align to hospital budget calendars.',
      'Commercial payer consolidation among PBMs (CVS Caremark, Express Scripts, OptumRx) and insurers affects outpatient device coverage. The Inflation Reduction Act Medicare drug negotiation provisions primarily target pharmaceuticals but signal broader federal cost-containment pressure that hospital committees reference when evaluating high-cost implantables.',
      'US import dependence varies by segment; domestic manufacturing reshoring initiatives and CHIPS-adjacent supply chain policies affect hospital willingness to dual-source. Tariff and trade policy shifts can reprice tender outcomes within quarters — longitudinal procurement research captures sensitivity syndicated audits miss.',
      'Physician ownership of ambulatory surgery centres and specialty clinics creates distinct adoption pathways from inpatient committees. BioNixus segments research by care setting — hospital OR, ASC, office-based lab — matching sample frames to the commercial channel under evaluation.',
      'Against IQVIA and global syndicated vendors, BioNixus differentiates on IDN/GPO-aware sampling, verified specialist recruitment, and decision-linked synthesis for launch, competitive defence, and M&A diligence — not subscription dashboards averaging away account-level nuance.',
    ],
  },
  uk: {
    slug: 'uk',
    label: 'United Kingdom',
    regulatorShort: 'MHRA',
    marketSize: 'GBP 12–14 billion',
    domesticFirms: 'ABHI member companies including Smith+Nephew and major multinationals',
    healthcareResearchPath: '/healthcare-market-research-uk',
    medDevicesReportPath: '/uk-medical-devices-market-report',
    relatedSlugs: ['germany', 'france'],
    languages: 'English',
    metricOne: { label: 'MedTech market 2026', value: 'GBP 12–14B', detail: 'ABHI industry estimate.' },
    metricTwo: { label: 'NHS Trusts', value: '223', detail: 'England NHS Trusts operating hospitals.' },
    metricThree: { label: 'NICE MedTech pathway', value: 'MTG / DG', detail: 'Medical Technologies Guidance and Diagnostics Guidance.' },
    executivePoints: [
      { title: 'MHRA UKCA/CE marking post-Brexit', body: 'UK-specific regulatory submissions and UK Responsible Person requirements add complexity for EU-manufactured devices. Research should map MHRA registration status alongside NHS adoption pathways.' },
      { title: 'NICE MedTech guidance shapes NHS uptake', body: 'Medical Technologies Guidance (MTG) and Diagnostics Guidance (DG) inform NHS England commissioning. Positive guidance accelerates adoption; absence creates committee hesitation even after regulatory clearance.' },
      { title: 'ICB formulary adoption lags national guidance', body: 'Forty-two Integrated Care Boards implement recommendations at different speeds. Sample design must reflect regional variation — London and Manchester versus rural ICBs.' },
    ],
    regulatoryParagraphs: [
      'The MHRA (Medicines and Healthcare products Regulatory Agency) regulates medical devices in Great Britain under UK MDR 2002 (as amended). Post-Brexit, UKCA marking applies for GB market placement alongside transitional CE recognition arrangements. Northern Ireland follows EU MDR under the Windsor Framework. Foreign manufacturers require a UK Responsible Person for GB market access.',
      'NICE evaluates medical technologies through Medical Technologies Guidance (MTG), Diagnostics Guidance (DG), and Interventional Procedures Programme (IP) reviews — distinct from pharmaceutical Technology Appraisals. Positive NICE guidance supports NHS England commissioning decisions; absence of guidance often delays adoption even when MHRA clearance exists. MedTech research must align evidence expectations with NICE evaluation criteria.',
      'NHS England Specialised Commissioning governs high-cost specialist devices and procedures. The Cancer Drugs Fund model for pharmaceuticals has analogues in specialised device commissioning — conditional funding pending further evidence. NHS Supply Chain and framework agreements influence tender pricing for commodity device categories.',
      'Integrated Care Boards (42 in England) implement formulary and pathway decisions with regional variation. Scotland (Scottish Medicines Consortium / Health Improvement Scotland), Wales (AWMSG), and Northern Ireland (HSC) maintain separate HTA processes. Research treating "UK" as homogeneous systematically misprices access timelines.',
      'UK post-market surveillance requirements under UK MDR include vigilance reporting and periodic safety update obligations. The MHRA participates in the Access Consortium with Health Canada, TGA, HSA, and Swissmedic — enabling reliance pathways for manufacturers with consortium-member approvals.',
      'NHS Long Term Plan investments in diagnostic capacity, surgical hubs, and digital transformation create procurement windows that device manufacturers must align to. Net-zero and sustainability criteria increasingly appear in NHS tender specifications — particularly for single-use device categories.',
    ],
    marketParagraphs: [
      'The UK medical devices market is estimated at GBP 12–14 billion in 2026 within an NHS budget of GBP 167 billion (2025/26). The NHS operates approximately 223 Trusts in England with world-leading cancer centres (Royal Marsden, Christie Manchester) and cardiac institutes driving early adoption.',
      'Smith+Nephew, Siemens Healthineers UK operations, and a dense SME base characterise domestic industry. Import dependence remains significant; Brexit-related supply chain adjustments shifted some sourcing patterns toward UK Responsible Person-registered distributors.',
      'Orthopaedic waiting lists exceeding seven hundred thousand patients (2024) drive demand for joint replacement and surgical capacity — affecting implant tender volumes and robotic-assisted surgery adoption. Diagnostic backlogs post-COVID accelerate POCT and imaging capital cycles.',
      'Private healthcare (Bupa, HCA, Spire) provides premium adoption corridors for innovator devices ahead of NHS formulary listing — segmenting research by public versus private setting reveals adoption sequencing invisible in blended national data.',
      'BioNixus UK programmes combine MHRA/NICE-aware research design with verified NHS consultant and biomedical engineering networks — delivering decision-ready evidence for launch, competitive defence, and international expansion planning.',
    ],
  },
  australia: {
    slug: 'australia',
    label: 'Australia',
    regulatorShort: 'TGA',
    marketSize: 'USD 9–11 billion',
    domesticFirms: 'AusMedtech member companies and multinational subsidiaries',
    healthcareResearchPath: '/healthcare-market-research-australia',
    medDevicesReportPath: '/australia-medical-devices-market-report',
    relatedSlugs: ['new-zealand', 'singapore'],
    languages: 'English',
    metricOne: { label: 'MedTech market 2026', value: 'USD 9–11B', detail: 'AusMedtech estimate.' },
    metricTwo: { label: 'TGA ARTG listing', value: '12 mo.', detail: 'Standard evaluation; Access Consortium reliance faster.' },
    metricThree: { label: 'Private hospital cover', value: '44%', detail: 'APRA 2024 — dual public/private pathways.' },
    executivePoints: [
      { title: 'TGA Access Consortium reliance', body: 'TGA accepts Health Canada, MHRA, FDA, and HSA assessments via reliance pathways — compressing ARTG listing to two to six months for eligible devices. Launch sequencing should leverage consortium credentials.' },
      { title: 'MSAC and Prostheses List govern device funding', body: 'Medical Services Advisory Committee evaluates procedures; Prostheses List covers implantables with major 2018–2023 price reforms. Research must map MBS item numbers and prostheses benefits relevant to your SKU.' },
      { title: 'Public/private split drives adoption sequencing', body: 'Forty-four percent hold private hospital cover — private hospitals often adopt innovator devices before PBS/MSAC-funded public pathways.' },
    ],
    regulatoryParagraphs: [
      'The TGA (Therapeutic Goods Administration) regulates medical devices through ARTG (Australian Register of Therapeutic Goods) listing. Class I devices require self-declaration; Class II–III require conformity assessment and TGA evaluation. Australia participates in the Access Consortium with Health Canada, MHRA, HSA, and Swissmedic — enabling reliance pathways that can reduce evaluation to approximately two months for devices already approved by consortium members.',
      'MSAC (Medical Services Advisory Committee) evaluates medical services and procedures for Medicare Benefits Schedule (MBS) funding. The Prostheses List governs private health insurance benefits for implantable devices — subject to major price reforms (forty to fifty percent cuts to orthopaedic and cardiac implant benefits, 2018–2023) that reshaped manufacturer pricing strategy.',
      'PBAC (Pharmaceutical Benefits Advisory Committee) governs drug PBS listing; device-drug combinations (e.g., drug-eluting devices) require coordinated evidence strategies. ACE (no relation to Singapore ACE) and state health technology assessment bodies provide supplementary guidance in some jurisdictions.',
      'Private Health Insurance Act requirements mean forty-four percent of Australians hold hospital cover — creating a private hospital adoption corridor distinct from public system MSAC timelines. Research must segment by public versus private setting and insurer tier (Gold/Silver/Bronze product categories).',
      'TGA post-market vigilance includes adverse event reporting and recall management. Software as a Medical Device and AI-enabled diagnostic platforms face evolving TGA guidance aligned with IMDRF principles.',
      'State-based procurement (NSW Health, Queensland Health, WA Health) operates framework agreements for hospital consumables and capital equipment — layered atop national MSAC decisions for procedure funding.',
    ],
    marketParagraphs: [
      'Australia\'s medical devices market is estimated at USD 9–11 billion in 2026 within total health expenditure of USD 220–240 billion (10.9% of GDP). Population 27.1 million with strong procedural volumes at major centres (Royal Melbourne, Royal Prince Alfred, Fiona Stanley).',
      'Access Consortium membership makes Australia a strategic parallel submission market alongside Canada and the UK for global launch sequencing. Domestic AusMedtech industry advocates for procurement reform and local manufacturing incentives.',
      'Orthopaedic and cardiac implant Prostheses List reforms compressed manufacturer net prices — adoption research must reflect post-reform committee behaviour, not pre-2018 benchmarks. Robotic surgery adoption grows at private hospitals ahead of public capital budget cycles.',
      'BioNixus Australia programmes combine TGA/MSAC-aware design with verified specialist networks across major public and private hospital systems — supporting launch, competitive defence, and Asia-Pacific portfolio planning.',
    ],
  },
  germany: {
    slug: 'germany',
    label: 'Germany',
    regulatorShort: 'BfArM / EU MDR',
    marketSize: 'EUR 30–33 billion',
    domesticFirms: 'BVMed member companies including Siemens Healthineers, B. Braun, Dräger',
    healthcareResearchPath: '/healthcare-market-research-germany',
    medDevicesReportPath: '/germany-medical-devices-market-report',
    relatedSlugs: ['france', 'switzerland'],
    languages: 'German (English for international KOL programmes)',
    metricOne: { label: 'MedTech market 2026', value: 'EUR 30–33B', detail: 'Largest in Europe; BVMed estimate.' },
    metricTwo: { label: 'Hospital beds', value: '487,000', detail: '5.8 per 1,000 — highest in Europe.' },
    metricThree: { label: 'GKV coverage', value: '~90%', detail: 'Statutory health insurance funds dominate.' },
    executivePoints: [
      { title: 'EU MDR notified body bottleneck', body: 'MDR transition extended timelines create competitive advantage for manufacturers with existing CE certificates. Research should map competitor NB status and clinical evidence gaps.' },
      { title: 'DRG procedure funding drives hospital economics', body: 'G-DRG system funds procedures; novel device cost must fit within DRG margins or justify NUB (new examination and treatment methods) supplementary payments.' },
      { title: 'University hospital KOLs predict national diffusion', body: 'Charité Berlin, Heidelberg, LMU Munich, and UKE Hamburg drive early adoption and clinical trial activity for surgical and diagnostic platforms.' },
    ],
    regulatoryParagraphs: [
      'Germany implements EU Medical Device Regulation (2017/745) through BfArM and notified bodies. MDR transition created certificate bottlenecks affecting launch timelines for Class IIb and III devices. UKCA/MHRA divergence post-Brexit adds parallel submission complexity for manufacturers serving both markets.',
      'G-DRG (German Diagnosis Related Groups) system funds hospital procedures; novel devices require NUB (Neue Untersuchungs- und Behandlungsmethoden) status for supplementary payment during evidence generation. Hospital economics research must map DRG impact and NUB application status.',
      'GKV (statutory health insurance) covers approximately ninety percent of the population through ~105 funds. Private PKV (~6.8 million) provides premium adoption corridors. Hospital formularies and KV (physician association) incentive schemes influence prescribing alongside formal HTA.',
      'BfArM DIMDI database registration and vigilance reporting obligations apply to all marketed devices. German Medizinproduktegesetz (MPG) transposes EU requirements with national specifics on implant registers (e.g., endoprosthesis registry).',
      'Siemens Healthineers, B. Braun, KARL STORZ, and Dräger anchor a strong domestic industry — competitive research must include German SME innovators alongside multinationals.',
      'Regional hospital ownership (public, charitable, private — Asklepios, Helios) creates distinct procurement behaviour. Sample frames should reflect Land (state) healthcare budget cycles and university hospital versus community hospital mix.',
    ],
    marketParagraphs: [
      'Germany\'s EUR 30–33 billion medical devices market is the largest in Europe, supported by 487,000 hospital beds (5.8 per 1,000 — highest in Europe) and EUR 440–460 billion total health expenditure. Charité, Heidelberg, and LMU Klinikum anchor national KOL networks.',
      'Aging demographics and high procedural volumes drive orthopaedic, cardiovascular, and diagnostic imaging demand. Digital health and hospital IT integration (KHZG funding) create procurement windows for connected device platforms.',
      'BioNixus Germany programmes deliver BfArM/MDR-aware research with verified KOL and hospital procurement networks — supporting EU5 launch, competitive defence, and GCC expansion from a German manufacturing base.',
    ],
  },
  france: {
    slug: 'france',
    label: 'France',
    regulatorShort: 'ANSM',
    marketSize: 'EUR 14–16 billion',
    domesticFirms: 'SNITEM member companies and major multinational operations',
    healthcareResearchPath: '/healthcare-market-research-france',
    medDevicesReportPath: '/france-medical-devices-market-report',
    relatedSlugs: ['germany', 'spain'],
    languages: 'French (English for global programme coordination)',
    metricOne: { label: 'MedTech market 2026', value: 'EUR 14–16B', detail: 'SNITEM estimate.' },
    metricTwo: { label: 'CHU hospitals', value: '32', detail: 'University hospital centres driving innovation adoption.' },
    metricThree: { label: 'LPPR listing', value: 'Required', detail: 'Liste des Produits et Prestations Remboursables for reimbursement.' },
    executivePoints: [
      { title: 'LPPR reimbursement listing', body: 'Devices require LPPR (Liste des Produits et Prestations Remboursables) inclusion for social security reimbursement — distinct from pharmaceutical CEPS pricing. Research must map LPPR category and add-on fee status.' },
      { title: 'GHT joint formularies', body: 'Groupements Hospitaliers de Territoire operate joint pharmacy formularies since 2016 — committee decisions affect multiple hospitals simultaneously.' },
      { title: 'ANSM and EUDAMED registration', body: 'EU MDR EUDAMED registration and ANSM national requirements apply; post-Brexit UK parallel submissions add complexity for Anglo-French portfolios.' },
    ],
    regulatoryParagraphs: [
      'ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé) regulates medical devices under EU MDR in mainland France. LPPR listing governs social security reimbursement for devices and procedures — a distinct pathway from pharmaceutical HAS/CEPS evaluation.',
      'HAS evaluates some high-cost devices through medical device economic committees; COMEDIMS (Commission de la Transparence) assessments apply where clinical benefit review is required. Hospital GHT (Groupement Hospitalier de Territoire) formularies implement listing decisions across hospital groups.',
      'France\'s 32 CHU (centres hospitaliers universitaires) drive clinical research and early adoption — AP-HP (Paris), HCL (Lyon), and CHU Toulouse anchor national KOL networks. AAP (Accès Précoce) early access pathways apply primarily to drugs but signal broader appetite for pre-reimbursement evaluation.',
      'EU MDR notified body capacity and EUDAMED registration requirements affect launch timelines. French language requirements for IFU and patient materials influence commercial rollout sequencing.',
      'Regional health agency (ARS) procurement frameworks layer atop national LPPR decisions for hospital capital equipment. Medical tourism (minimal versus Germany/UK) does not materially affect device adoption research sample frames.',
      'BioNixus France programmes respect ANSM/LPPR context with French-language fieldwork and verified CHU/community hospital networks.',
    ],
    marketParagraphs: [
      'France\'s EUR 14–16 billion medical devices market operates within EUR 280–300 billion total health expenditure (11.9% of GDP). SNITEM represents domestic manufacturers; import dependence remains significant in high-technology segments.',
      'Orthopaedic waiting times and surgical hub investments drive implant and robotic surgery adoption. Diabetes technology growth follows SGLT-2 and GLP-1 market dynamics affecting device portfolio strategy.',
      'BioNixus delivers ANSM-aware MedTech research with French fieldwork capability — supporting EU5 launch sequencing and competitive intelligence.',
    ],
  },
  japan: {
    slug: 'japan',
    label: 'Japan',
    regulatorShort: 'PMDA',
    marketSize: 'USD 38–43 billion',
    domesticFirms: 'Olympus, Terumo, and multinational subsidiaries',
    healthcareResearchPath: '/healthcare-market-research-japan',
    medDevicesReportPath: '/japan-medical-devices-market-report',
    relatedSlugs: ['south-korea', 'china'],
    languages: 'Japanese (English for global HQ coordination)',
    metricOne: { label: 'MedTech market 2026', value: 'USD 38–43B', detail: 'Third largest globally.' },
    metricTwo: { label: 'Hospital beds', value: '12.1/1,000', detail: 'Highest bed density in OECD.' },
    metricThree: { label: 'Sakigake review', value: '6 months', detail: 'Priority pathway for innovative devices.' },
    executivePoints: [
      { title: 'PMDA/Shonin and NHI listing cycle', body: 'MHLW approval must align with biannual NHI price listing (April/October). Missing a cycle delays revenue by six months — research timelines should map committee and pricing windows.' },
      { title: 'DPC hospital funding model', body: 'Diagnosis Procedure Combination per-diem payment shapes hospital device economics. Novel procedures require DPC code assignment for reimbursement.' },
      { title: 'Super-ageing society drives segment growth', body: 'Over twenty-eight percent of population over sixty-five — orthopaedic, cardiovascular, and home-care device demand grows structurally.' },
    ],
    regulatoryParagraphs: [
      'PMDA (Pharmaceuticals and Medical Devices Agency) evaluates device marketing submissions under MHLW oversight. Sakigake Designation provides six-month priority review for devices addressing unmet medical need in Japan. Japanese clinical data requirements are easing but bridging studies remain common for novel technologies.',
      'NHI (National Health Insurance) price listing occurs biannually (April and October) through Chuikyo (Central Social Insurance Medical Council). New device pricing uses cost-comparison or similar-efficacy methods with innovation premiums (H1/H2/H3 adders). Biannual price revisions cut prices five to seven percent on average — affecting lifecycle revenue planning.',
      'DPC/PDPS (Diagnosis Procedure Combination) funding model pays hospitals per-diem by diagnosis-procedure group — novel devices must secure DPC code assignment for procedure reimbursement. Foreign Manufacturer Accreditation (FMA) and Marketing Authorization Holder (MAH) requirements apply to imported devices.',
      'Japan\'s 12.1 beds per 1,000 (highest OECD) reflects long hospital stays — device utilization patterns differ materially from US outpatient-centric models. University hospitals (~82) drive clinical trial and early adoption activity.',
      'Post-market surveillance and re-examination requirements apply under PMDA vigilance rules. Software as a Medical Device guidance aligns with international harmonisation efforts.',
      'BioNixus Japan programmes coordinate with Japanese-language field partners for verified specialist recruitment — supporting PMDA-aware launch and Asia-Pacific portfolio strategy.',
    ],
    marketParagraphs: [
      'Japan\'s USD 38–43 billion medical devices market is third largest globally, driven by super-ageing demographics (124 million population, >28% over sixty-five). Olympus and Terumo anchor domestic industry; import dependence remains significant in high-technology segments.',
      'Robotic surgery, endoscopy, and diagnostic imaging represent high-value categories. Home-care and remote monitoring devices grow as community-based care expands under regional integrated care reforms.',
      'BioNixus supports Japan market entry research with PMDA/NHI context and verified KOL networks at major university hospitals.',
    ],
  },
  china: {
    slug: 'china',
    label: 'China',
    regulatorShort: 'NMPA',
    marketSize: 'USD 80–95 billion',
    domesticFirms: 'Thousands of domestic manufacturers; import share declining in commodity segments',
    healthcareResearchPath: '/healthcare-market-research-china',
    medDevicesReportPath: '/china-medical-devices-market-report',
    relatedSlugs: ['japan', 'singapore'],
    languages: 'Mandarin Chinese (English for multinational HQ programmes)',
    metricOne: { label: 'MedTech market 2026', value: 'USD 80–95B', detail: 'Second largest globally.' },
    metricTwo: { label: 'Hospitals', value: '~36,000', detail: 'Tier 3 Grade A centres drive premium adoption.' },
    metricThree: { label: 'VBP tenders', value: 'Annual', detail: 'Volume-based procurement with significant price cuts.' },
    executivePoints: [
      { title: 'NMPA registration and local agent requirements', body: 'Class II/III devices require NMPA registration with increasing local clinical evidence expectations. Foreign manufacturers require domestic legal agent and often local testing.' },
      { title: 'VBP price compression', body: 'Volume-Based Procurement national tenders cut prices fifty to ninety percent in included categories — research must segment VBP-affected versus non-VBP premium segments.' },
      { title: 'Tier 3 hospital concentration', body: '~3,000 Tier 3 Grade A hospitals drive innovator adoption and clinical trial activity — national averages obscure account-level dynamics.' },
    ],
    regulatoryParagraphs: [
      'NMPA (National Medical Products Administration) regulates medical devices under classification rules aligned with international norms. Class II and III devices require registration with increasing local clinical evidence requirements. Unique Device Identification (UDI) system implementation progresses nationally.',
      'Volume-Based Procurement (VBP) national tenders apply to commodity device categories with dramatic price compression — manufacturers must segment research between VBP-governed and premium innovator segments where hospital self-pay and private channels sustain pricing.',
      'NHSA (National Healthcare Security Administration) governs reimbursement; NRDL updates primarily target drugs but signal broader cost-containment direction affecting device budgets. Provincial procurement offices implement hospital tender cycles.',
      'Tier 3 Grade A hospitals (~3,000) concentrate high-technology adoption and clinical research. Tier 2 and Tier 1 facilities follow multi-year lag patterns — sample frames must match commercial channel strategy.',
      'Domestic manufacturer competitiveness grows in orthopaedic, IVD, and imaging segments — competitive research must include local champions alongside multinationals.',
      'BioNixus China programmes coordinate with Mandarin field partners respecting NMPA and hospital data governance requirements.',
    ],
    marketParagraphs: [
      'China\'s USD 80–95 billion medical devices market is second largest globally within USD 1.3–1.5 trillion health expenditure. 1.41 billion population with rising chronic disease burden drives structural demand growth.',
      'VBP reforms reshaped commodity segment economics; innovator manufacturers focus on Tier 3 centres, private hospitals, and direct-to-patient channels where permitted. Robotic surgery and advanced imaging remain high-growth premium segments.',
      'BioNixus supports China market intelligence with NMPA/VBP-aware research design and verified hospital stakeholder access at major referral centres.',
    ],
  },
  singapore: {
    slug: 'singapore',
    label: 'Singapore',
    regulatorShort: 'HSA',
    marketSize: 'USD 2.3–2.8 billion',
    domesticFirms: 'Regional HQ operations and emerging local innovators',
    healthcareResearchPath: '/healthcare-market-research-singapore',
    medDevicesReportPath: '/singapore-medical-devices-market-report',
    relatedSlugs: ['australia', 'malaysia'],
    languages: 'English (Mandarin, Malay, Tamil in patient research)',
    metricOne: { label: 'MedTech market 2026', value: 'USD 2.3–2.8B', detail: 'EDB / HSA estimates.' },
    metricTwo: { label: 'Access Consortium', value: 'Member', detail: 'Parallel submissions with TGA, MHRA, Health Canada.' },
    metricThree: { label: 'Public clusters', value: '3', detail: 'SingHealth, NHG, NUHS anchor adoption.' },
    executivePoints: [
      { title: 'HSA verification pathway', body: 'Six-month verification review for devices approved by Access Consortium members — Singapore often leads ASEAN launch sequencing for consortium credentials.' },
      { title: 'ACE health technology assessment', body: 'Agency for Care Effectiveness evaluates high-cost technologies for SDL (Standard Drug List) and MAF (Medication Assistance Fund) subsidy.' },
      { title: 'Medical tourism premium corridor', body: 'Private hospitals (Parkway, Raffles) serve regional patients — adoption research should segment public cluster versus private premium settings.' },
    ],
    regulatoryParagraphs: [
      'HSA (Health Sciences Authority) regulates medical devices through PRISM (Product Registration Information Management System). Access Consortium verification pathway provides six-month review for devices approved by TGA, MHRA, Health Canada, FDA, or Swissmedic — making Singapore a strategic parallel submission market.',
      'ACE (Agency for Care Effectiveness) conducts health technology assessments for MOH subsidy decisions. Standard Drug List (SDL) listing required for public hospital subsidy; Medication Assistance Fund (MAF) covers selected high-cost therapies for lower-income patients.',
      'Three public hospital clusters — SingHealth (SGH, NCCS), NHG (TTSH), NUHS (NUH) — govern majority of public sector adoption. Private groups (Parkway Pantai, Raffles) serve medical tourism and premium segments.',
      'MediShield Life, Medisave, and Medifund financing framework affects patient co-pay and device affordability research. Chronic Disease Management Programme (CDMP) covers selected conditions relevant to diabetes device categories.',
      'Singapore serves as ASEAN regional HQ for multinationals — research supports hub-to-market expansion into Malaysia, Indonesia, and Thailand with harmonised evidence architecture.',
      'BioNixus Singapore programmes leverage HSA/ACE context with verified specialist networks across public clusters and private hospitals.',
    ],
    marketParagraphs: [
      'Singapore\'s USD 2.3–2.8 billion medical devices market punches above its weight as an ASEAN regulatory and commercial hub. 5.9 million population with USD 85,000+ GDP per capita and world-class public hospital infrastructure.',
      'Access Consortium membership enables efficient multi-market launch with Australia, Canada, and UK. EDB actively recruits medtech manufacturers to regional headquarters.',
      'BioNixus supports Singapore and ASEAN expansion research with HSA-aware design and verified KOL access at NCCS, NUH, and major private centres.',
    ],
  },
  italy: {
    slug: 'italy',
    label: 'Italy',
    regulatorShort: 'AIFA / EU MDR',
    marketSize: 'EUR 12–14 billion',
    domesticFirms: 'Confindustria Dispositivi Medici members',
    healthcareResearchPath: '/healthcare-market-research-italy',
    medDevicesReportPath: '/italy-medical-devices-market-report',
    relatedSlugs: ['spain', 'germany'],
    languages: 'Italian',
    metricOne: { label: 'MedTech market 2026', value: 'EUR 12–14B', detail: 'Confindustria Dispositivi Medici.' },
    metricTwo: { label: 'SSN regions', value: '21', detail: 'Regional PTR formulary autonomy.' },
    metricThree: { label: 'EU MDR', value: 'Active', detail: 'Notified body certification required.' },
    executivePoints: [
      { title: 'Regional PTR formulary variation', body: 'Twenty-one regions implement Piano Terapeutico Regionale at different speeds — Lombardy and Emilia-Romagna adopt faster than southern regions.' },
      { title: 'SSN procurement and tender cycles', body: 'Central procurement agency (Consip) and regional tenders govern hospital device purchasing — mapping tender calendars prevents mistimed launch.' },
      { title: 'Academic IRCCS centres', body: 'Istituti di Ricovero e Cura a Carattere Scientifico drive oncology and cardiovascular innovation adoption nationally.' },
    ],
    regulatoryParagraphs: [
      'Italy implements EU MDR through AIFA coordination and notified body certification. Device reimbursement flows through regional SSN (Servizio Sanitario Nazionale) budgets and PTR (Piano Terapeutico Regionale) formularies — twenty-one regions create significant adoption variation.',
      'Ministero della Salute circulars and regional health authority directives govern hospital capital equipment procurement. Medtech budget caps at regional level affect high-cost robot and imaging purchases.',
      'IRCCS research hospitals (San Raffaele Milan, Humanitas, European Institute of Oncology) anchor national KOL networks and clinical trial activity.',
      'EU MDR EUDAMED registration and vigilance reporting apply. Post-Brexit UK submissions require parallel MHRA strategy for Anglo-Italian portfolios.',
      'Italian language IFU and patient material requirements affect commercial rollout. BioNixus Italy programmes use Italian fieldwork with verified specialist networks.',
      'Price transparency and anti-corruption (Legge 190/2012) requirements influence manufacturer-hospital interaction rules — research protocols respect institutional compliance policies.',
    ],
    marketParagraphs: [
      'Italy\'s EUR 12–14 billion devices market operates within EUR 175–190 billion health expenditure. Aging population and orthopaedic demand drive implant volumes; robotic surgery adoption concentrates at IRCCS and large regional hospitals.',
      'Regional variation in PTR adoption creates multi-speed market — national syndicated data obscures Lombardy versus Calabria dynamics that determine realistic launch sequencing.',
      'BioNixus Italy programmes deliver EU MDR-aware research with regional segmentation and verified KOL access.',
    ],
  },
  spain: {
    slug: 'spain',
    label: 'Spain',
    regulatorShort: 'AEMPS',
    marketSize: 'EUR 10–12 billion',
    domesticFirms: 'AdvaMed Spain member companies',
    healthcareResearchPath: '/healthcare-market-research-spain',
    medDevicesReportPath: '/spain-medical-devices-market-report',
    relatedSlugs: ['france', 'italy'],
    languages: 'Spanish (Catalan, Basque in regional modules)',
    metricOne: { label: 'MedTech market 2026', value: 'EUR 10–12B', detail: 'AdvaMed Spain estimate.' },
    metricTwo: { label: 'Autonomous communities', value: '17', detail: 'Separate SNS procurement pathways.' },
    metricThree: { label: 'EU MDR', value: 'Active', detail: 'AEMPS national coordination.' },
    executivePoints: [
      { title: 'Autonomous community formulary lag', body: 'Catalonia (CatSalut) and Basque Country adopt faster than some rural communities — twelve to eighteen month variation post-national listing.' },
      { title: 'IPT therapeutic positioning', body: 'Informe de Posicionamiento Terapéutico positions devices within therapeutic classes before CIPM price negotiation.' },
      { title: 'Hospital Guía Farmacoterapéutica', body: 'Hospital pharmacy committees implement Guía Farmacoterapéutica listing three to six months post-regional adoption.' },
    ],
    regulatoryParagraphs: [
      'AEMPS (Agencia Española de Medicamentos y Productos Sanitarios) coordinates EU MDR implementation in Spain. SNS universal coverage through seventeen autonomous communities creates regional procurement variation.',
      'IPT (Informe de Posicionamiento Terapéutico) and CIPM (Comisión Interministerial de Precios) govern reimbursement positioning and pricing for devices entering SNS funding.',
      'Regional health services (CatSalut, SERMAS Madrid, SAS Andalusia) operate distinct tender and formulary processes — research must segment by target autonomous community.',
      'EU MDR notified body capacity and EUDAMED requirements apply. Spain frequently serves as reference member state for EU MRP procedures.',
      'Hospital capital equipment purchases align to regional budget cycles and EU Next Generation EU recovery fund healthcare investments (2021–2026).',
      'BioNixus Spain programmes use Spanish fieldwork with autonomous community-aware sample design.',
    ],
    marketParagraphs: [
      'Spain\'s EUR 10–12 billion devices market within EUR 120–130 billion health expenditure serves 47.9 million population. High diabetes prevalence (14.8% adults) drives monitoring and therapeutic device demand.',
      'Regional adoption variation is among the widest in EU5 — Catalonia and Madrid versus slower rural communities require segmented research, not national averages.',
      'BioNixus supports Spain MedTech research with AEMPS context and verified hospital networks across target autonomous communities.',
    ],
  },
  switzerland: {
    slug: 'switzerland',
    label: 'Switzerland',
    regulatorShort: 'Swissmedic',
    marketSize: 'CHF 6–7 billion',
    domesticFirms: 'Medtech Switzerland members including Roche Diagnostics ecosystem',
    healthcareResearchPath: '/healthcare-market-research-switzerland',
    medDevicesReportPath: '/pharmaceutical-market-research-switzerland',
    relatedSlugs: ['germany', 'france'],
    languages: 'German, French, Italian (region-dependent)',
    metricOne: { label: 'MedTech market 2026', value: 'CHF 6–7B', detail: 'Medtech Switzerland estimate.' },
    metricTwo: { label: 'Access Consortium', value: 'Member', detail: 'With Health Canada, TGA, MHRA, HSA.' },
    metricThree: { label: 'Premium market', value: 'High GDP/cap', detail: 'Early adopter for innovator technologies.' },
    executivePoints: [
      { title: 'Swissmedic and Access Consortium', body: 'Swissmedic participates in Access Consortium — parallel submissions with Health Canada, TGA, MHRA, and HSA compress multi-market launch timelines.' },
      { title: 'KVG mandatory insurance', body: 'Krankenversicherungsgesetz mandatory health insurance covers essential devices; supplementary insurance covers premium technologies.' },
      { title: 'Cantonal hospital ownership', body: 'Twenty-six cantons own or regulate public hospitals — procurement varies by canton (Zurich, Bern, Geneva).' },
    ],
    regulatoryParagraphs: [
      'Swissmedic regulates medical devices under Medizinprodukteverordnung (MepV) aligned with EU MDR principles despite non-EU status. Access Consortium membership enables international submission reliance.',
      'KVG (Krankenversicherungsgesetz) mandatory insurance and VVG supplementary insurance create dual reimbursement pathways — research should segment public-mandatory versus supplementary coverage.',
      'Cantonal hospital systems (Zurich, Bern, Geneva, Vaud) operate distinct procurement. University hospitals (Inselspital Bern, CHUV Lausanne, USZ Zurich) drive KOL activity.',
      'Swiss price level is among the highest globally — premium innovator adoption often precedes EU5 listing; Switzerland serves as early-revenue market for global launches.',
      'Multilingual requirements (German, French, Italian) affect IFU and patient material localisation. BioNixus Switzerland programmes segment by linguistic region.',
      'Medtech Switzerland industry association advocates for innovation-friendly procurement — research connects policy context to account prioritisation.',
    ],
    marketParagraphs: [
      'Switzerland\'s CHF 6–7 billion medtech market punches above population weight (8.7 million) with highest OECD health spending per capita. Roche, Zambon, and dense SME ecosystem characterise domestic industry.',
      'Access Consortium credentials make Switzerland a strategic parallel market with Canada and Australia for global launch sequencing.',
      'BioNixus supports Swiss MedTech research with Swissmedic context and verified KOL networks at major university hospitals.',
    ],
  },
  denmark: {
    slug: 'denmark',
    label: 'Denmark',
    regulatorShort: 'Danish Medicines Agency',
    marketSize: 'DKK 25–30 billion',
    domesticFirms: 'Medicoindustrien members including Ambu and Coloplast',
    healthcareResearchPath: '/healthcare-market-research-denmark',
    medDevicesReportPath: '/pharmaceutical-market-research-denmark',
    relatedSlugs: ['germany', 'uk'],
    languages: 'Danish (English widely used in KOL programmes)',
    metricOne: { label: 'MedTech market 2026', value: 'DKK 25–30B', detail: 'Medicoindustrien estimate.' },
    metricTwo: { label: 'Coloplast / Ambu HQ', value: 'Denmark', detail: 'Global medtech champions headquartered nationally.' },
    metricThree: { label: 'EU MDR', value: 'Active', detail: 'Danish Medicines Agency coordination.' },
    executivePoints: [
      { title: 'Regional hospital groups', body: 'Five regions (Region Hovedstaden, Midtjylland, etc.) govern hospital procurement post-2007 structural reform.' },
      { title: 'Ambu and Coloplast ecosystem', body: 'Denmark hosts global device champions — competitive research must map domestic innovator activity alongside multinational portfolios.' },
      { title: 'Digital health leadership', body: 'Denmark\'s national digital health infrastructure (MedCom, Sundhed.dk) accelerates connected device and SaMD adoption.' },
    ],
    regulatoryParagraphs: [
      'Danish Medicines Agency (Lægemiddelstyrelsen) implements EU MDR nationally. Five regional health authorities govern hospital procurement after the 2007 structural reform.',
      'Denmark\'s universal tax-funded healthcare system provides broad device coverage; regional tenders govern hospital purchasing. Ambu and Coloplast anchor a strong export-oriented domestic industry.',
      'National digital health records and MedCom standards accelerate SaMD and remote monitoring adoption — research should map digital integration requirements.',
      'EU MDR notified body certification and EUDAMED registration apply. Denmark frequently participates in Nordic collaborative procurement (SKI, NHN).',
      'English proficiency among specialists enables bilingual research programmes for global HQ coordination.',
      'BioNixus Denmark programmes respect regional procurement context with verified hospital and specialist networks.',
    ],
    marketParagraphs: [
      'Denmark\'s medtech sector exports globally through Ambu, Coloplast, and William Demant (Demant) — domestic market size belies international strategic importance. 5.9 million population with high health expenditure per capita.',
      'Regional hospital groups concentrate procedural volume; digital health leadership creates differentiated adoption pathways for connected devices.',
      'BioNixus supports Denmark MedTech research with EU MDR context and Nordic expansion intelligence.',
    ],
  },
  'new-zealand': {
    slug: 'new-zealand',
    label: 'New Zealand',
    regulatorShort: 'Medsafe',
    marketSize: 'NZD 2–2.5 billion',
    domesticFirms: 'NZ Medtech members and Fisher & Paykel Healthcare',
    healthcareResearchPath: '/healthcare-market-research-new-zealand',
    medDevicesReportPath: '/pharmaceutical-market-research-new-zealand',
    relatedSlugs: ['australia', 'singapore'],
    languages: 'English (Te Reo Māori for public sector modules)',
    metricOne: { label: 'MedTech market 2026', value: 'NZD 2–2.5B', detail: 'NZ Medtech / Fisher & Paykel ecosystem.' },
    metricTwo: { label: 'Fisher & Paykel', value: 'Global HQ', detail: 'Respiratory and neonatal device champion.' },
    metricThree: { label: 'PHARMAC', value: 'Device listing', detail: 'Schedule and hospital funding pathways.' },
    executivePoints: [
      { title: 'Medsafe WAND database', body: 'Web Assisted Notification of Devices (WAND) database registration required; Australia-New Zealand mutual recognition arrangements simplify trans-Tasman launch.' },
      { title: 'PHARMAC and DHB procurement', body: 'PHARMAC governs pharmaceutical listing; District Health Boards (now Health NZ) procure hospital devices through national and regional tenders.' },
      { title: 'Fisher & Paykel export hub', body: 'Domestic champion Fisher & Paykel Healthcare anchors respiratory device innovation — competitive landscape research must include local export leaders.' },
    ],
    regulatoryParagraphs: [
      'Medsafe regulates medical devices under WAND (Web Assisted Notification of Devices) registration. Trans-Tasman mutual recognition with TGA simplifies dual Australia-New Zealand launch for many device categories.',
      'Health NZ (formerly DHB system) procures hospital devices through national contracts and regional tenders. PHARMAC Schedule primarily governs drugs but signals broader cost-containment direction.',
      'Accident Compensation Corporation (ACC) covers device-related procedures for injury claims — relevant for orthopaedic and rehabilitation device categories.',
      'Fisher & Paykel Healthcare anchors domestic respiratory and neonatal device industry with global export reach. Research should map local innovator competitive activity.',
      'Te Whatu Ora (Health NZ) structural reforms (2022) consolidated DHBs — procurement centralisation affects tender timing and committee structure.',
      'BioNixus New Zealand programmes leverage trans-Tasman regulatory context with verified specialist networks.',
    ],
    marketParagraphs: [
      'New Zealand\'s NZD 2–2.5 billion medtech market serves 5.2 million population with Fisher & Paykel Healthcare as global respiratory device champion. Trans-Tasman regulatory alignment with Australia supports joint launch sequencing.',
      'Health NZ consolidation creates national procurement scale — research must map new committee structures versus legacy DHB behaviour.',
      'BioNixus supports New Zealand MedTech research with Medsafe context and Australia comparative modules.',
    ],
  },
  'south-korea': {
    slug: 'south-korea',
    label: 'South Korea',
    regulatorShort: 'MFDS',
    marketSize: 'USD 10–12 billion',
    domesticFirms: 'KMDIA members; Samsung Medison, Osstem, strong domestic industry',
    healthcareResearchPath: '/healthcare-market-research-south-korea',
    medDevicesReportPath: '/south-korea-medical-devices-market-report',
    relatedSlugs: ['japan', 'china'],
    languages: 'Korean (English for global HQ coordination)',
    metricOne: { label: 'MedTech market 2026', value: 'USD 10–12B', detail: 'KMDIA estimate.' },
    metricTwo: { label: 'Hospital beds', value: '11.5/1,000', detail: 'Second highest OECD bed density.' },
    metricThree: { label: 'Big 5 hospitals', value: '5', detail: 'Samsung, Asan, Severance, SNUH, ASGMC.' },
    executivePoints: [
      { title: 'MFDS and NHIS listing', body: 'MFDS approval followed by NHIS Essential Drug List and HIRA assessment — among fastest OECD access pathways for innovative devices when evidence is strong.' },
      { title: 'Big 5 hospital formulary', body: 'Samsung Medical Center, Asan, Severance, SNUH, and ASGMC formulary decisions predict national diffusion for high-technology devices.' },
      { title: 'Domestic manufacturer competitiveness', body: 'Samsung Medison, Osstem, and growing local champions compete in imaging and dental segments — research must include domestic competitive set.' },
    ],
    regulatoryParagraphs: [
      'MFDS (Ministry of Food and Drug Safety) regulates medical devices with K-CTD dossier format. NHIS listing and HIRA (Health Insurance Review and Assessment) economic evaluation govern reimbursement.',
      'Big 5 Seoul hospital formulary decisions drive national KOL influence — Samsung Medical Center, Asan Medical Center, Severance, Seoul National University Hospital, and ASGMC anchor adoption.',
      '11.5 hospital beds per 1,000 (second OECD after Japan) reflects care delivery patterns affecting device utilization. Rapid aging population drives orthopaedic and cardiovascular demand.',
      'Domestic manufacturers (Samsung Medison, Osstem Implant) compete aggressively in imaging and dental — competitive research must include local champions.',
      'MFDS accepts ICH member country clinical data with bridging where required. BioNixus Korea programmes coordinate Korean-language fieldwork.',
      'HIRA risk-sharing agreements common for high-cost devices — research should map economic evidence expectations.',
    ],
    marketParagraphs: [
      'South Korea\'s USD 10–12 billion devices market serves 51.7 million population with world-leading hospital bed density and fast MFDS/NHIS access pathways for innovative technologies.',
      'K-beauty adjacent aesthetic device market and dental implant segments add distinct research needs beyond hospital capital equipment.',
      'BioNixus supports Korea MedTech research with MFDS/NHIS context and verified Big 5 hospital network access.',
    ],
  },
  poland: {
    slug: 'poland',
    label: 'Poland',
    regulatorShort: 'URPL',
    marketSize: 'PLN 18–22 billion',
    domesticFirms: 'Polmedica and growing domestic manufacturing base',
    healthcareResearchPath: '/healthcare-market-research-poland',
    medDevicesReportPath: '/pharmaceutical-market-research-poland',
    relatedSlugs: ['germany', 'uk'],
    languages: 'Polish',
    metricOne: { label: 'MedTech market 2026', value: 'PLN 18–22B', detail: 'Fastest-growing EU market by volume.' },
    metricTwo: { label: 'Population', value: '38 million', detail: 'Largest Central European market.' },
    metricThree: { label: 'EU MDR', value: 'Active', detail: 'URPL national coordination.' },
    executivePoints: [
      { title: 'NFZ reimbursement pathways', body: 'Narodowy Fundusz Zdrowia governs public reimbursement; private pay grows in orthopaedic and aesthetic segments.' },
      { title: 'EU cohesion fund investments', body: 'EU-funded hospital modernisation drives capital equipment procurement cycles through 2027.' },
      { title: 'Cross-border EU patient flows', body: 'EU directive cross-border care creates referral patterns affecting border region adoption (Germany, Czechia).' },
    ],
    regulatoryParagraphs: [
      'URPL (Office for Registration of Medicinal Products) implements EU MDR in Poland. NFZ (Narodowy Fundusz Zdrowia) governs public reimbursement with growing HTA requirements through AOTMiT agency.',
      'EU cohesion and recovery funds drive hospital modernisation and diagnostic capacity investment — tender calendars align to fund disbursement schedules.',
      'Private healthcare (Lux Med, Enel-Med, Medicover) grows faster than public sector — segmenting research by public versus private setting reveals adoption sequencing.',
      'Polish language fieldwork required for community hospital and patient modules. BioNixus Poland programmes use verified Polish specialist networks.',
      'Cross-border care under EU directive affects border region utilization patterns — relevant for Germany-adjacent voivodeships.',
      'Domestic manufacturing grows in consumables and orthopaedic segments — competitive set includes emerging local champions.',
    ],
    marketParagraphs: [
      'Poland\'s PLN 18–22 billion medtech market is Central Europe\'s largest by population (38 million) with EU-funded hospital investment driving capital equipment cycles.',
      'NFZ cost-containment pressure increases alongside private pay growth — dual-pathway research prevents mispriced access strategy.',
      'BioNixus supports Poland MedTech research with URPL/NFZ context and EU5 comparative modules.',
    ],
  },
  malaysia: {
    slug: 'malaysia',
    label: 'Malaysia',
    regulatorShort: 'MDA',
    marketSize: 'MYR 8–10 billion',
    domesticFirms: 'Malaysia Medical Device Association members',
    healthcareResearchPath: '/healthcare-market-research-malaysia',
    medDevicesReportPath: '/pharmaceutical-market-research-malaysia',
    relatedSlugs: ['singapore', 'australia'],
    languages: 'English, Malay, Mandarin, Tamil',
    metricOne: { label: 'MedTech market 2026', value: 'MYR 8–10B', detail: 'MMDA / MOH estimates.' },
    metricTwo: { label: 'Dual sector', value: 'Public + private', detail: 'MOH public and growing private hospital chains.' },
    metricThree: { label: 'ASEAN hub', value: 'Growing', detail: 'Regional manufacturing and distribution centre.' },
    executivePoints: [
      { title: 'MDA registration and conformity', body: 'Medical Device Authority (MDA) registration under ASEAN Medical Device Directive alignment — reference country approvals accelerate review.' },
      { title: 'MOH versus private hospital split', body: 'IHH (Pantai, Gleneagles), KPJ, and Columbia Asia private chains adopt innovator devices faster than MOH public hospitals.' },
      { title: 'Halal and cultural considerations', body: 'Device materials and patient-facing design require cultural validation in Malay-majority patient research modules.' },
    ],
    regulatoryParagraphs: [
      'Medical Device Authority (MDA) regulates devices under Malaysia\'s Medical Device Act 2012 aligned with ASEAN AMDD. Reference country approvals (FDA, CE, TGA) accelerate registration.',
      'MOH public hospitals procure through central contracts; private chains (IHH, KPJ) operate distinct formulary processes with faster innovator adoption.',
      'Malaysia aspires to ASEAN medtech manufacturing hub status — research supports hub-to-region expansion into Indonesia, Thailand, and Philippines.',
      'Multilingual fieldwork (Malay, English, Mandarin, Tamil) standard for patient and community physician modules.',
      'MyHDW (Malaysia Health Data Warehouse) digital infrastructure grows — connected device research should map integration requirements.',
      'BioNixus Malaysia programmes combine MDA context with GCC comparative modules for manufacturers serving both ASEAN and MENA.',
    ],
    marketParagraphs: [
      'Malaysia\'s MYR 8–10 billion medtech market serves 34 million population with dual public-private healthcare pathways and ASEAN distribution hub ambitions.',
      'Medical tourism through private hospitals (Prince Court, Gleneagles KL) creates premium adoption corridor distinct from MOH procurement.',
      'BioNixus supports Malaysia MedTech research with MDA-aware design and verified specialist networks across public and private systems.',
    ],
  },
  brazil: {
    slug: 'brazil',
    label: 'Brazil',
    regulatorShort: 'ANVISA',
    marketSize: 'USD 11–13 billion',
    domesticFirms: 'ABIMO members; strong domestic orthopaedic and dental industry',
    healthcareResearchPath: '/healthcare-market-research/brazil',
    medDevicesReportPath: '/brazil-medical-devices-market-report',
    relatedSlugs: ['usa', 'germany'],
    languages: 'Portuguese',
    metricOne: { label: 'MedTech market 2026', value: 'USD 11–13B', detail: 'ABIMO estimate.' },
    metricTwo: { label: 'ANVISA classes', value: 'I–IV', detail: 'Risk-based registration pathways.' },
    metricThree: { label: 'Private insurance', value: '~50M', detail: 'ANS-regulated supplementary coverage.' },
    executivePoints: [
      { title: 'ANVISA GGMED registration', body: 'Class III/IV devices require ANVISA registration with Portuguese Module 1; RDC 751/2022 updated good manufacturing practices.' },
      { title: 'SUS versus ANS private split', body: 'SUS universal public system (~75% dependency) versus ANS private plans (~50 million) create dual adoption pathways with different evidence expectations.' },
      { title: 'Import tariff and local content', body: 'Thirty to sixty percent effective import rates drive local manufacturing partnerships — research should map distributor and local production strategy.' },
    ],
    regulatoryParagraphs: [
      'ANVISA (Agência Nacional de Vigilância Sanitária) regulates medical devices under risk Classes I–IV. GGMED division manages registration with Portuguese-language Module 1 requirements. RDC 751/2022 updated GMP requirements.',
      'SUS (Sistema Único de Saúde) public procurement through CONITEC HTA for high-cost technologies; ANS (Agência Nacional de Saúde Suplementar) governs private plan coverage through Rol de Procedimentos.',
      'Import tariffs (thirty to sixty percent effective) and local content preferences drive manufacturing partnership strategy — research maps distributor capability and local assembly options.',
      'Rede D\'Or, Hapvida, and Fleury anchor private hospital adoption; public university hospitals (USP, UNIFESP, UFRJ) drive KOL activity.',
      'Portuguese fieldwork mandatory for physician and patient modules. BioNixus Brazil programmes use verified Brazilian specialist networks.',
      'Mercosur regulatory harmonisation efforts affect southern cone expansion — Brazil research supports Argentina and Chile comparative modules.',
    ],
    marketParagraphs: [
      'Brazil\'s USD 11–13 billion devices market serves 218 million population — Latin America\'s largest. Dual SUS/public and ANS/private pathways require segmented research design.',
      'Domestic orthopaedic and dental manufacturers compete aggressively; import tariffs reshape multinational pricing strategy.',
      'BioNixus supports Brazil MedTech research with ANVISA context, Portuguese fieldwork, and LATAM expansion intelligence.',
    ],
  },
};

export function getDevelopedMarketMedtechPath(slug: DevelopedMarketMedtechSlug): string {
  return `/${slug}-medtech-market-research`;
}

export function getDevelopedMarketMedtechExpandedContent(
  slug: DevelopedMarketMedtechSlug,
): ServiceLandingExpandedContent {
  const country = DEVELOPED_MARKET_MEDTECH_COUNTRIES[slug];
  return buildExpandedContent(country);
}

export function getDevelopedMarketMedtechCountry(slug: DevelopedMarketMedtechSlug): DevelopedMarketMedtechCountry {
  return DEVELOPED_MARKET_MEDTECH_COUNTRIES[slug];
}

export type DevelopedMarketMedtechListicleFirm = {
  rank: number;
  name: string;
  type: string;
  hq: string;
  anchor: string;
  overview: string;
  strengths: string[];
};

export function getDevelopedMarketMedtechListiclePath(slug: DevelopedMarketMedtechSlug): string {
  return `/insights/top-medtech-market-research-companies-${slug}-2026`;
}

export function buildDevelopedMarketMedtechListicleFirms(
  country: DevelopedMarketMedtechCountry,
): DevelopedMarketMedtechListicleFirm[] {
  const bofu = getDevelopedMarketMedtechPath(country.slug);
  const name = country.label;
  return [
    {
      rank: 1,
      name: 'BioNixus',
      type: 'International MedTech Specialist',
      hq: 'USA (HQ) / UK / Egypt',
      anchor: 'bionixus',
      overview: `BioNixus delivers MedTech and medical devices market research in ${name} with ${country.regulatorShort}-aware hospital procurement research, clinician adoption studies, and decision-ready synthesis. See the dedicated company page at ${bofu}.`,
      strengths: [
        `MedTech programmes in ${name}`,
        `${country.languages} fieldwork where required`,
        'Hospital procurement and KOL depth',
        'Mixed quant + qual design',
        'GCC expansion intelligence for international manufacturers',
      ],
    },
    {
      rank: 2,
      name: 'IQVIA',
      type: 'Global Life Sciences Data',
      hq: 'USA (global)',
      anchor: 'iqvia',
      overview: `IQVIA provides medical device market analytics, hospital audit data, and custom primary research in ${name} through its global life sciences network.`,
      strengths: ['Syndicated device audit data', 'Global benchmarking', 'Large-scale quant infrastructure'],
    },
    {
      rank: 3,
      name: 'Kantar',
      type: 'Global Network',
      hq: 'UK (global)',
      anchor: 'kantar',
      overview: `Kantar operates custom and syndicated research in ${name} with healthcare and B2B practices supporting MedTech brand tracking and physician insight programmes.`,
      strengths: ['Brand tracking at scale', 'Multi-sector coverage', 'Established field networks'],
    },
    {
      rank: 4,
      name: 'Ipsos',
      type: 'Global Network',
      hq: 'France (global)',
      anchor: 'ipsos',
      overview: `Ipsos delivers healthcare and device market research in ${name} with quantitative rigour and public affairs capability for regulated categories.`,
      strengths: ['Healthcare specialty practice', 'Quantitative rigour', 'Global methodology standards'],
    },
    {
      rank: 5,
      name: 'Regional specialist agencies',
      type: 'Local / Regional',
      hq: `${name} and international`,
      anchor: 'regional',
      overview: `Several regional boutiques execute MedTech fieldwork in ${name}. Validate device-specific methodology, hospital access, and ${country.regulatorShort} context before award.`,
      strengths: ['Local hospital networks', 'Flexible project sizing', 'Fast feasibility checks'],
    },
  ];
}

export function buildDevelopedMarketMedtechListicleFaqs(country: DevelopedMarketMedtechCountry) {
  const listiclePath = getDevelopedMarketMedtechListiclePath(country.slug);
  const bofuPath = getDevelopedMarketMedtechPath(country.slug);
  return [
    {
      q: `What are the top MedTech market research companies in ${country.label}?`,
      a: `Leading options include BioNixus, IQVIA, Kantar, Ipsos, and regional specialist agencies serving ${country.label}. BioNixus ranks first for ${country.regulatorShort}-aware hospital procurement research and clinician adoption studies.`,
    },
    {
      q: `How do I choose a MedTech market research partner in ${country.label}?`,
      a: 'Validate hospital access, device category experience, sample verification controls, regulatory context, and decision-ready deliverables — not slide volume alone.',
    },
    {
      q: `How does this list relate to pharmaceutical market research in ${country.label}?`,
      a: `This guide covers MedTech and medical devices industry selection. For pharmaceutical company-intent pages, use ${country.healthcareResearchPath} and related healthcare BOFU URLs.`,
    },
    {
      q: `Where is the BioNixus MedTech services page for ${country.label}?`,
      a: `See ${bofuPath} for company-intent MedTech market research programmes; this listicle compares firms independently.`,
    },
    {
      q: `Can MedTech research in ${country.label} connect to GCC benchmarking?`,
      a: 'Yes. BioNixus runs parallel modules comparing local adoption with SFDA, MOHAP, and GCC hospital procurement intelligence using harmonised instruments.',
    },
    {
      q: `What device segments do ${country.label} research firms typically cover?`,
      a: 'Cardiovascular, orthopaedics, diagnostic imaging, IVD, diabetes technology, surgical robotics, wound care, and hospital capital equipment — segment feasibility should be validated at proposal stage.',
    },
    {
      q: `How long does a typical MedTech study take in ${country.label}?`,
      a: 'Focused HCP surveys complete in four to six weeks; full mixed-method programmes with hospital procurement depth typically run eight to twelve weeks depending on specialty and geography.',
    },
    {
      q: `Is this ${country.label} MedTech firms guide updated for 2026?`,
      a: `Yes. Rankings and capability notes reflect ${country.label} regulatory and procurement context as of 2026, including ${country.regulatorShort} requirements.`,
    },
  ];
}

export function getDevelopedMarketMedtechListicleLandscapeParagraphs(
  country: DevelopedMarketMedtechCountry,
): string[] {
  return [
    `The ${country.label} medical devices market is estimated at ${country.marketSize} in 2026, shaped by ${country.regulatorShort} regulation, hospital procurement cycles, and ${country.domesticFirms}. Manufacturers launching or defending device portfolios need primary research that maps prescriber behaviour to committee and payer reality — not syndicated averages alone.`,
    `MedTech market research in ${country.label} differs from pharmaceutical research: sample frames prioritise biomedical engineers, hospital value-analysis committees, and procedure specialists; evidence must address total cost of ownership, training burden, and maintenance contracts alongside clinical efficacy.`,
    `Global syndicated vendors provide audit data; specialist firms like BioNixus add verified hospital access, ${country.regulatorShort}-aware study design, and decision-linked synthesis for launch sizing, competitive defence, and international expansion planning.`,
    `For company-intent programmes — not firm comparison — see our dedicated MedTech market research page for ${country.label}. For broader healthcare context, start from the healthcare market research hub and ${country.healthcareResearchPath}.`,
  ];
}
